SANUWAVE prelim Q1 revenue $5.7-5.9M, up 51-56% YoY, highest Q1 ever

SANUWAVE Health, Inc.

2024-Q1 EPS reported $0.00 revenue$5,786,000

Preliminary Q1 2024 revenue $5.7M-$5.9M, up 51%-56% vs Q1 2023; highest Q1 in company history.
UltraMist revenue grew >55% YoY, accounting for ~95% of total revenue.
UltraMist applicator sales set all-time quarterly record, exceeding 65% of total revenue.
Full Q1 2024 results expected in mid-May; guidance reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SANUWAVE Health, Inc. reported first quarter 2024 (ended March 31, 2024) results: revenue $5.7 million to $5.9 million.

Period: first quarter 2024 (ended March 31, 2024)
Revenue: $5.7 million to $5.9 million
Result: preliminary results

Exact text from the filing

SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-019005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.